Melatonin based therapies for delirium and dementia

Area of Science:

• Neuroscience
• Geriatric Psychiatry
• Pharmacology

Background:

• Melatonin levels naturally decrease with aging.
• Low melatonin is associated with cognitive decline, delirium, and dementia.
• Melatonin has neuroprotective and pleiotropic effects beyond sleep promotion.

Purpose of the Study:

• To review the role of melatonin and its analogs in geriatric psychiatric disorders.
• To evaluate the efficacy and safety of melatonergic medications for delirium and dementia.
• To compare melatonergic medications with traditional treatments like antipsychotics and benzodiazepines.

Main Methods:

• Review of existing literature, including animal and human studies.
• Analysis of recent clinical trials on melatonin and its analogs.
• Examination of safety and side effect profiles.

Main Results:

• Melatonin and its analogs demonstrate potential in preventing and treating delirium.
• These agents may be beneficial in managing dementia symptoms.
• Melatonergic medications offer a favorable safety profile compared to sedatives and antipsychotics.

Conclusions:

• Melatonin and its analogs are promising therapeutic options for geriatric psychiatric diseases.
• These medications can be used alone or in combination for managing delirium and dementia.
• Their established safety profile makes them attractive alternatives to existing treatments.